Key result
High multimorbidity burden linked to ~52% greater MACE risk after PCI versus low burden.
Why the study?
The association between cumulative multimorbidity burden and both clinical and functional outcomes after PCI in contemporary real-world practice remains incompletely characterized.
Does high multimorbidity burden increase the risk of adverse clinical and functional outcomes in patients undergoing PCI?
Population
1,238 consecutive patients who underwent PCI
Comparison
High-burden group (≥ 2 chronic diseases) vs low-burden group (0–1 chronic disease)
Design
Single-center retrospective cohort study
Follow-up
Median 36 months (IQR 28–42)
Authors
Loading...
May identify high-risk PCI patients for closer follow-up; leaves open whether targeted interventions reduce MACE.
Cohort (n=1,238)
No
Does high multimorbidity burden increase the risk of adverse clinical and functional outcomes in patients undergoing PCI?
Effect estimate: HR 1.52 (95% CI 1.18-1.96)
Absolute Event Rate: 30.4% vs 17%
p-value: p=0.001
In patients undergoing PCI, a higher multimorbidity burden is significantly associated with increased long-term MACE and poorer functional recovery at 12 months.
Wu et al. (2026) conducted a cohort in Coronary artery disease undergoing percutaneous coronary intervention (n=1,238). High multimorbidity burden (≥2 chronic diseases) vs. Low multimorbidity burden (0–1 chronic disease) was evaluated on Major adverse cardiovascular events (MACE) (HR 1.52, 95% CI 1.18-1.96, p=0.001). High multimorbidity burden (≥2 chronic diseases) was associated with a significantly increased risk of major adverse cardiovascular events after PCI compared to low burden (HR 1.52).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: